Parkman Healthcare Partners’s Apogee Therapeutics APGE Stock Holding History

Parkman Healthcare Partners’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-77,686	Closed	-$6.54M	–	80
2026 Q1	$6.54M	Sell	77,686 -52,383	-40%	-$3.8M	0.67%	49
2025 Q4	$9.82M	Buy	130,069 +24,238	+23%	+$1.53M	0.93%	40
2025 Q3	$4.2M	Buy	105,831 +50,427	+91%	+$1.93M	0.44%	66
2025 Q2	$2.41M	Buy	55,404 +8,741	+19%	+$333K	0.28%	79
2025 Q1	$1.74M	Sell	46,663 -38,337	-45%	-$1.48M	0.21%	78
2024 Q4	$3.85M	Buy	+85,000	New	+$4.33M	0.51%	53

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Parkman Healthcare Partners's APGE Position: Q2 2026 in Review

Parkman Healthcare Partners sold out of Apogee Therapeutics (APGE) in Q2 2026, closing a stake of 77,686 shares — an estimated $6.54M sold.

Parkman Healthcare Partners first reported a position in APGE in Q4 2024 and held it in 6 quarters. The position peaked at $9.82M in Q4 2025. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

Parkman Healthcare Partners reported no remaining Apogee Therapeutics position as of Q2 2026 after selling out during the quarter.
Parkman Healthcare Partners sold 77,686 Apogee Therapeutics shares in Q2 2026, an estimated $6.54M.
Parkman Healthcare Partners first reported a position in Apogee Therapeutics in Q4 2024 and held it in 6 quarters.
Parkman Healthcare Partners's Apogee Therapeutics position peaked at $9.82M in Q4 2025.
289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Parkman Healthcare Partners's 13F filing for Q2 2026, filed 14 Aug 2026.